Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.
This practice parameter describes treatment with stimulant medication. It uses an evidence-based medicine approach derived from a detailed literature review and expert consultation. Stimulant medications in clinical use include methylphenidate, dextroamphetamine, mixed-salts amphetamine, and pemoline. It carries FDA indications for treatment of attention-deficit/hyperactivity disorder and narcolepsy.
Greenhill
Laurence L
LL
Pliszka
Steven
S
Dulcan
Mina K
MK
Bernet
William
W
Arnold
Valerie
V
Beitchman
Joseph
J
Benson
R Scott
RS
Bukstein
Oscar
O
Kinlan
Joan
J
McClellan
Jon
J
Rue
David
D
Shaw
Jon A
JA
Stock
Saundra
S
D000293:Adolescent; D000328:Adult; D000662:Amphetamines / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D001921:Brain / Q000187:drug effects*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D000075202:Contraindications; D016903:Drug Monitoring; D019317:Evidence-Based Medicine; D006801:Humans; D008774:Methylphenidate / Q000627:therapeutic use; D009290:Narcolepsy / Q000188:drug therapy; D010389:Pemoline / Q000627:therapeutic use; D011600:Psychopharmacology; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D014481:United States
D000662:Amphetamines; D000697:Central Nervous System Stimulants; D011619:Psychotropic Drugs; D008774:Methylphenidate; D010389:Pemoline